Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07226999, led by Pfizer, and recruiting on the registry. Official title: A global phase 2/3 interventional study of PF-08634404 in combination with chemotherapy in participants with extensive stage small cell lung cancer. Planned enrolment is 550 participants (estimated). The study started in 2025-12-09 and primary completion is expected in 2030-06-14. No results have been posted on ClinicalTrials.gov.